- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
Aclaris Therapeutics Highlights Upcoming Atopic Dermatitis Data, ITK Progress
Biotech company outlines clinical milestones for large-molecule and small-molecule pipeline at healthcare conference.
Published on Mar. 10, 2026
Got story updates? Submit your updates here. ›
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, outlined multiple near-term development milestones across its pipeline during a presentation at the Leerink Partners Global Healthcare Conference. Management emphasized upcoming data readouts for its atopic dermatitis programs, including the TSLP monoclonal antibody ATI-045 in a Phase 2 study and the bispecific ATI-052 in Phase 1 trials. The company also discussed progress with its oral small-molecule ITK inhibitor franchise, including plans to file an IND for a 'next-gen' ITK program in the second half of the year.
Why it matters
Aclaris is positioning itself as a leader in immunology and inflammation, with a focus on developing novel therapies for chronic skin conditions like atopic dermatitis. The upcoming data readouts and pipeline advancements could help validate the company's scientific approach and drive further investment and interest in its programs.
The details
Aclaris outlined plans for its large-molecule programs, including the TSLP monoclonal antibody ATI-045 in a Phase 2 study in moderate-to-severe atopic dermatitis, with results expected in the latter part of 2026. The company also discussed ATI-052, a bispecific that combines the ATI-045 TSLP antibody with an IL-4 receptor component, which is currently in SAD/MAD studies with Phase 1b trials enrolling in moderate asthma and severe AD, targeting readouts by the end of 2026. On the small-molecule side, Aclaris highlighted ATI-2138, which is Phase 2-ready with a long-term toxicology package, as the company selects a lead indication. The company also plans to file an IND for a 'next-gen' ITK program, ATI-9494, in the second half of 2026, touting improved potency and extended half-life compared to competitor molecules.
- ATI-045 Phase 2 results expected in late 2026.
- ATI-052 Phase 1b readouts targeted for end of 2026.
- ATI-9494 IND filing planned for second half of 2026.
The players
Aclaris Therapeutics
A clinical-stage biopharmaceutical company focused on developing novel therapies for dermatologic and inflammatory conditions.
Neal Walker
Chairman and CEO of Aclaris Therapeutics.
Hugh Davis
President and COO of Aclaris Therapeutics.
Roland Kolbeck
Chief Scientific Officer of Aclaris Therapeutics.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
